common.study.topics.clinical

Transdermal Nicotine on Response Inhibition in Schizophrenia

common.study.values.description

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

The purpose of this study is to test whether nicotine, a drug that activates receptors called nicotinic acetylcholine receptors in the brain, improves the ability to make or withhold responses to faces that are either emotionally neutral or emotionally negative. This study will also test whether the drug affects brain activity while making or withholding responses using electroencephalography. Previous studies in people with schizophrenia have shown that more errors in response to negative emotional cues are related to greater likelihood of impulsive aggressive behavior. Therefore, the aim of this study is to determine whether nicotine might be a new strategy to reduce aggressive behavior. The investigators' goal is 25 individuals with schizophrenia and 25 healthy controls to complete the study at Vanderbilt.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Nicotine Patch, 7 Mg/24 Hr

Nicotine patch, 7 mg/24 hour will be applied to the skin.

Drug - Placebo patch

Placebo skin patch will be applied to the skin.

participant.views.study.view.additional

participant.views.study.view.scientific-title

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

common.study.values.clinical-trial-id

NCT03838484

participant.views.study.view.id

bDkEAa